Clinical Trial Update: An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

View source ↗

Summary

An observational study conducted in Belgium assessing the use of darolutamide as part of combination therapy for metastatic hormone-sensitive prostate cancer in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Status: COMPLETED